Roche Holding AG (HAM:RHOA) FFO


HAM:RHOA Roche Holding AG HAM:RHOA
77 GF Score
Price €362.75
GF Value €285.76
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Roche Holding AG FFO?

FFO (Funds from operations) only applies to REITs.

HAM:RHOA
77GF Score
Roche Holding AG HAM:RHOA
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Roche Holding AG (HAM:RHOA) Overvalued in 2026?

Based on GuruFocus' analysis, Roche Holding AG stock appears to be overvalued. The current stock price of €362.75 is trading 26.9% above its estimated GF Value™ of €285.76. GuruFocus considers Roche Holding AG to be Modestly Overvalued.

Key valuation signals for HAM:RHOA:

  • FFO:
  • GF Value™: €285.76 vs. price of €362.75 (26.9% above fair value)
  • GF Score™: 77/100 with 7 warning signs

No single metric tells the full story. See the HAM:RHOA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Roche Holding AG Business Description

Address Grenzacherstrasse 124, Basel, CHE, 4070
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 40% of pharmaceutical sales, and centralized and point-of-care diagnostics for two-thirds of diagnostic-related sales.
77GF Score

Get the complete analysis for HAM:RHOA

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€362.75
Price
€285.76
GF Value